20-F: NeuroSense Reports Strong PrimeC ALS Trial Data, Faces Funding Needs

NeuroSense Therapeutics Ltd. reported positive long-term survival data for its lead ALS drug candidate, PrimeC, from its Phase 2b PARADIGM study, while also highlighting a substantial doubt about its ability to continue as a going concern without additional financing.

Summary

• NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's.
• The company's lead candidate, PrimeC, an extended-release oral formulation of ciprofloxacin and celecoxib, has received Orphan Drug Designation from the FDA and EMA for ALS.
• The Phase 2b PARADIGM trial for PrimeC in ALS met primary safety and tolerability endpoints and showed statistically significant slowing of disease progression in high-risk patients.
• Long-term follow-up data from the PARADIGM study (up to 18 months post-treatment) demonstrated a median survival of 36.3 months for continuous PrimeC treatment compared to 21.4 months for placebo-switch patients, representing a 70% increase in median survival and a substantial reduction in death risk.
• PrimeC also showed significant modulation of key ALS-related microRNAs and favorable trends in iron metabolism markers.
• The FDA cleared the initiation of a pivotal Phase 3 clinical trial for PrimeC in ALS in November 2025, with patient enrollment aimed for 2026 upon securing strategic resources.
• The company is preparing for a pre-New Drug Submission (pre-NDS) meeting with Health Canada in May 2026, anticipating a potential NDS submission by Q3 2026 for early commercialization approval.
• NeuroSense initiated a Phase 2 study (RoAD) for PrimeC in mild-to-moderate Alzheimer's Disease in Q4 2023, with initial positive results in September and October 2025 showing enhanced neuroplasticity and reduction in AD-associated microRNAs.
• The company reported a net loss of $11.1 million for the year ended December 31, 2025, compared to $10.2 million in 2024, with an accumulated deficit of $47.8 million.
• Cash and cash equivalents stood at $0.2 million as of December 31, 2025, down from $3.378 million in 2024, indicating a critical need for additional financing.
• Research and Development expenses increased by 9.3% to $6.227 million in 2025, primarily due to higher share-based compensation, offset by decreased subcontractor and consulting expenses.
• General and Administrative expenses increased by 15.6% to $4.858 million in 2025, mainly due to increased share-based compensation.
• A binding term sheet with a leading global pharmaceutical company for PrimeC development and commercialization in certain territories was concluded in March 2026 due to organizational changes at the counterparty, leading to ongoing interactions with additional potential partners.
• The company expects to be classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes for 2025 and future years.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While the long-term clinical data for PrimeC in ALS is highly positive and statistically significant, the company's severe liquidity issues and 'going concern' warning, coupled with the recent failure to finalize a major partnership, present substantial financial risks that overshadow the clinical progress.

Positives

• PrimeC's Phase 2b PARADIGM trial met primary safety and tolerability endpoints.
• Statistically significant slowing of disease progression was observed in high-risk ALS patients in the PARADIGM trial.
• 12-month analysis of PARADIGM showed significant improvement in ALSFRS-R decline rate and survival rates for patients on continuous PrimeC treatment.
• Long-term follow-up (up to 18 months post-PARADIGM) demonstrated a 70% increase in median survival for continuous PrimeC patients (36.3 months vs. 21.4 months for placebo-switch) and a substantial reduction in death risk, which was statistically significant.
• Positive 12-month biomarker data from PARADIGM showed decreased ferritin and increased transferrin levels, indicating alleviation of ALS pathology.
• Significant modulation of key ALS-related microRNAs was observed in the PARADIGM trial, supporting PrimeC's multi-target mechanism.
• FDA clearance was received in November 2025 to initiate the pivotal Phase 3 clinical trial for PrimeC in ALS.
• The FDA agreed with the proposed CMC development plan for PrimeC's 505(b)(2) marketing application.
• PrimeC received Orphan Drug Designation from both the FDA and EMA for ALS, and SME status from the EMA.
• Initial positive results from the Phase 2 RoAD clinical trial for PrimeC in Alzheimer's Disease showed enhanced neuroplasticity and no treatment-related toxicity.
• New findings from PARADIGM plasma samples indicated statistically significant reductions in multiple AD-associated microRNAs, supporting PrimeC's potential as a disease-modifying therapy for AD.
• Safety analysis from the Phase 2 AD trial indicated a favorable tolerability profile with no serious adverse events or new safety signals.
• Production of PrimeC has been successfully scaled up to commercial levels, with stability data supporting a 36-month shelf life.
• The company holds U.S. patents for ALS treatment methods (expiring 2038), Alzheimer's treatment methods (expiring 2043), and PrimeC formulations (expiring 2042), with international equivalents.

Negatives

• The company incurred a net loss of $11.1 million in 2025, following a $10.2 million loss in 2024, and has an accumulated deficit of $47.8 million.
• Cash and cash equivalents decreased significantly to $0.2 million as of December 31, 2025, from $3.378 million in 2024.
• There is substantial doubt about the company's ability to continue as a going concern without securing additional financing.
• A binding term sheet with a leading global pharmaceutical company for PrimeC development and commercialization was concluded in March 2026 due to the counterparty's organizational changes and strategic priorities, indicating a setback in securing a major partnership.
• The company has a limited operating history and has not generated any revenue to date, relying heavily on external financing.
• The company expects to continue incurring significant losses and negative cash flows for the foreseeable future.
• The company expects to be classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, which could have adverse tax consequences for U.S. investors.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses, equity deficit, negative working capital, and negative cash flows.
• Requirement for substantial additional financing to achieve goals; failure to obtain capital could delay, limit, reduce, or terminate product development and commercialization.
• Limited operating history and history of significant losses and negative cash flows make future viability difficult to assess.
• Raising additional capital may cause dilution to shareholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• Dependence on the success of PrimeC, including obtaining regulatory approval to market in the United States.
• Inability to obtain regulatory approval for product candidates, which involves a lengthy, expensive, and uncertain process.
• Limited clinical data generated for product candidates to date, with no guarantee that later clinical trials will be successful.
• Limited experience in conducting clinical trials and never having obtained approval for any product candidates.
• Potential for undesirable side effects from PrimeC or other product candidates, which could prevent marketing approval or market acceptance, increase commercialization costs, or force cessation of operations.
• Significant competition from large and experienced biopharmaceutical companies, potentially preventing significant market penetration.
• Lack of experience in marketing or distributing products and no internal capability to do so, requiring reliance on third parties.
• Risks associated with collaborations with third parties for development or commercialization, including non-performance or termination.
• Failure to manage growth effectively could disrupt business operations.
• Inability to attract and retain senior management and key scientific personnel could hinder product development and commercialization.
• Internal computer systems or those of contractors may fail or suffer security breaches, disrupting drug development programs.
• Inability to enforce covenants not to compete under applicable employment laws.
• Risk of employees, contractors, or consultants engaging in misconduct or improper activities, including noncompliance with regulatory standards and insider trading.
• Exchange rate fluctuations between the U.S. Dollar and the New Israeli Shekel may negatively affect earnings.
• Adverse effects from current or future unfavorable economic and market conditions, including military conflicts and geopolitical events.
• Inadequate efforts to obtain, protect, or enforce patents and other intellectual property rights could harm competitive position.
• Subject to claims of infringing, misappropriating, or violating third-party intellectual property rights.
• Limited or no protection from issued patents and patent applications, and potential for delays in clinical trials to reduce patent protection period.
• Inability to protect the confidentiality of trade secrets could harm business and competitive position.
• Changes in U.S. patent law could diminish the value of patents.
• Failure to comply with procedural, documentary, and fee payment requirements for patent protection could lead to loss of patent rights.
• Inability to protect intellectual property rights throughout the world, especially in countries with weaker IP laws.
• Involvement in lawsuits to protect or enforce intellectual property could be expensive, time-consuming, and delay commercialization.
• Claims for remuneration or royalties for assigned service invention rights by employees under Israeli law.
• If the FDA does not conclude that PrimeC satisfies Section 505(b)(2) requirements, the approval pathway could be significantly longer and more costly.
• Impact of current and future legislation affecting the healthcare industry, including healthcare reform, on reimbursement and product pricing.
• Orphan Drug Designation may not ensure market exclusivity, leading to earlier competition.
• Ongoing regulatory obligations and review post-approval, potentially leading to significant additional expenses or withdrawal of approval.
• Relationships with healthcare professionals and other parties may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, and privacy laws.
• Difficulty in profitably selling product candidates if coverage and reimbursement are limited by government authorities and/or third-party payor policies.
• Legislative or regulatory healthcare reforms may make it more difficult and costly to obtain regulatory approval and market products.
• Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could delay product development and approval.
• Failure to maintain compliance with Nasdaq's continued listing requirements could lead to delisting.
• Market price fluctuation of ordinary shares and warrants, leading to potential loss of investment.
• Lack of equity research analyst coverage or unfavorable commentary could cause share price decline.
• Future sales of ordinary shares could reduce market price.
• Significant share ownership by officers, directors, and affiliates may limit other shareholders' ability to influence corporate matters.
• Never paid cash dividends and do not anticipate paying any in the foreseeable future.
• Increased costs and management time due to operating as a public company in the United States.
• Warrants may not have any value if the ordinary share price does not exceed the exercise price.
• Classification as a passive foreign investment company (PFIC) for U.S. federal income tax purposes could cause adverse tax consequences for U.S. investors.
• As a foreign private issuer, the company follows certain home country corporate governance practices instead of Nasdaq requirements, potentially offering less protection to investors.
• Loss of foreign private issuer status could significantly increase regulatory and compliance costs.
• Reduced disclosure requirements as an emerging growth company may make shares less attractive to investors.
• Scrutiny of sustainability and ESG initiatives could increase costs or adversely impact business.
• Conditions in Israel, including military conflicts and political instability, may affect operations, despite no material adverse effect to date.

Future Outlook

The company anticipates continuing to incur significant expenses and operating losses for the foreseeable future as it advances its product candidates through clinical trials, seeks regulatory approval, and pursues commercialization. Future operations are dependent on securing substantial additional financing through equity or debt, collaborative arrangements, or a combination thereof. The company aims to initiate the pivotal Phase 3 clinical trial for PrimeC in ALS in 2026 upon securing strategic resources and anticipates a potential NDS submission to Health Canada by Q3 2026 for early commercialization.

Management Comments

• "Our future operations are dependent upon the identification and successful completion of equity or debt financing and the achievement of profitable operations at an indeterminate time in the future."
• "We believe PrimeC’s multifunctional mechanism of action has the potential to significantly prolong lifespan and improve ALS patients’ quality of life, thereby reducing the burden of this debilitating disease on both patients and healthcare systems."
• "We are preparing for trial initiation and aim to have the first patient enrolled in the coming months upon securing the strategic resources needed to launch the trial."
• "The security situation in the region remains highly fluid, and we are unable to predict if, when, or on what terms, this escalation will be resolved."
• "Our operations have not been adversely affected by this situation, and it has not experienced disruptions to its clinical studies. As such, its clinical and business development activities remain on track."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry for neurodegenerative diseases is highly competitive, with numerous large and specialty pharmaceutical and biotechnology companies actively developing potentially disease-modifying therapeutics for ALS, Alzheimer's, and Parkinson's. Key competitors mentioned include Biogen, Amylyx Pharmaceuticals, Novartis, Eli Lilly, Roche, and others. NeuroSense's strategy of targeting multiple disease pathways with a fixed-dose combination drug like PrimeC is a differentiated approach in a field where existing treatments offer only modest effects and are often limited to specific genetic mutations (e.g., Qalsody for SOD1-ALS). The high annual cost of ALS ($180,000 per patient) underscores the significant market opportunity for effective treatments, but also the intense pressure on pricing and reimbursement from payors.

Comparison to Industry Standards

• PrimeC's long-term survival benefit of 36.3 months median survival for continuous treatment compared to 21.4 months for placebo-switch patients (70% increase) is a significant improvement compared to existing FDA-approved drugs like Rilutek (riluzole) and Radicava (edaravone), which typically extend life expectancy by only a few months.
• Qalsody (tofersen), approved for SOD1-ALS, targets only approximately 2% of the overall ALS population, whereas PrimeC's multi-target mechanism aims for a broader patient population.
• Competitors like Brainstorm Cell Therapeutics' NurOwn completed a pivotal Phase 3 trial but did not achieve its primary endpoint, highlighting the difficulty in this therapeutic area, making PrimeC's positive Phase 2b and long-term follow-up results notable.
• Clene's CNM-Au8, while not meeting its primary endpoint in a Phase 3 trial, showed a reduction in the risk of death, similar to the survival benefit observed with PrimeC, suggesting a shared focus on extending patient life.
• The company's reliance on third-party contract manufacturers is a common industry practice, but the successful scale-up of PrimeC production to commercial levels in May 2025 demonstrates progress in manufacturing readiness compared to earlier-stage competitors.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• In August and December 2024, the company entered into share purchase agreements with certain senior management and the chief executive officer.
• In December 2024, the company's CEO, CFO, CMO, CTO, and COO signed a waiver letter regarding bonuses they were entitled to for the years 2022-2024 in their capacity as shareholders, resulting in a reclassification of $1,434 thousand to additional paid-in capital.
• In December 2025, the company's shareholders approved a grant of 476,435 restricted shares to non-management directors as equity compensation in lieu of deferred cash fees ($410 thousand).
• In December 2025, the company's shareholders approved a grant of 315,000 restricted shares to non-management directors as equity compensation.
• In December 2025, the company's shareholders approved the issuance of restricted ordinary shares to the CEO in lieu of cash bonuses for 2022, 2023, and 2024 (approximately $930,000), plus an additional 106,967 restricted shares for share count adjustment.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing capital raises and potential future equity issuances. The 'going concern' warning indicates a high risk to investment value. Positive clinical data for PrimeC could increase long-term value if commercialized successfully, but the failure of a major partnership is a setback. PFIC status could lead to adverse U.S. federal income tax consequences for U.S. holders.
• **Employees:** The company's growth and development of product candidates offer potential for continued employment and career advancement. Equity-based compensation plans are in place to incentivize and retain personnel. However, the 'going concern' risk could impact job security if financing is not secured.
• **Customers (Future Patients):** Positive clinical trial results for PrimeC offer hope for a new, potentially disease-modifying treatment for ALS and Alzheimer's, addressing significant unmet medical needs. The company's focus on patient advocacy groups underscores a commitment to patient perspectives.
• **Suppliers/Contractors:** The company relies heavily on third-party contract manufacturers and CROs. Continued operations and future clinical trials depend on these relationships and the company's ability to fund them. Delays in payments or termination of contracts due to financial constraints could impact these relationships.
• **Creditors:** The 'going concern' warning and accumulated deficit indicate elevated risk for creditors. The company's ability to satisfy liabilities in the ordinary course of business is uncertain without additional financing.

Next Steps

• Secure substantial additional financing through public or private sales of debt or equity securities, or collaborative arrangements.
• Initiate the pivotal Phase 3 clinical trial for PrimeC in ALS in 2026, contingent on securing strategic resources.
• Prepare for and conduct a pre-New Drug Submission (pre-NDS) meeting with Health Canada in May 2026.
• Submit a New Drug Submission (NDS) to Health Canada for PrimeC by Q3 2026 for potential early commercialization approval.
• Report combined clinical and biomarker outcomes from the Phase 2 AD study in Q1 2026.
• Further explore StabiliC's mode of action for Parkinson's Disease and assess its ability to affect PD-related hallmarks using in-vitro patient-derived cells and in-vivo rodent models.
• Continue interactions with additional potential partners for PrimeC development and commercialization.
• Monitor and maintain compliance with Nasdaq's continued listing requirements, including the Minimum Market Value of Listed Securities (MVLS) Rule.

Key Dates

Recommendation

While NeuroSense Therapeutics has demonstrated highly promising and statistically significant long-term survival data for PrimeC in ALS, a critical positive, the company's severe financial distress, including a 'going concern' warning and a substantial accumulated deficit, presents an immediate and significant risk. The recent failure to secure a major pharmaceutical partnership further exacerbates funding challenges. The stock is highly speculative. A 'Hold' recommendation acknowledges the strong clinical potential but advises caution due to the precarious financial position and the urgent need for substantial capital to advance its pipeline to commercialization. Investors should monitor financing developments closely.

Keywords

NeuroSense Therapeutics, PrimeC, ALS, Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Alzheimer's Disease, Parkinson's Disease, Clinical Trials, Phase 3, Orphan Drug, Biotechnology, Pharmaceutical, Drug Development, SEC Filing, Form 20-F, Biomarkers, Survival Data, Going Concern, Capital Raise, Nasdaq, Ciprofloxacin, Celecoxib, MicroRNA, Neuroinflammation, Iron Accumulation, RoAD Study, StabiliC